Catalog No.
PHD88101
Species reactivity
Human
Host species
Rabbit
Isotype
IgG
Clonality
Polyclonal
Immunogen
E. coli - derived recombinant Human WEE1 (Asn290-Ser573).
Tested applications
ELISA: 1:4000-1:8000, IHC: 1:50-1:100, WB: 1:1000-1:4000
Target
Wee1A kinase, WEE1, Wee1-like protein kinase, WEE1hu
Purification
Purified by antigen affinity column.
Accession
P30291
Applications
ELISA, IHC, WB
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Precision Medicine in High-Grade Serous Ovarian Cancer: Targeted Therapies and the Challenge of Chemoresistance., PMID:40141188
Controversies in the management of mucinous ovarian tumors., PMID:40054128
Targeting refractory diffuse large B cell lymphoma by CAR-WEE1 T-cells: In vitro evaluation., PMID:39820427
Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors., PMID:39560862
Evolving treatment paradigms for platinum-resistant ovarian cancer: An update narrative review., PMID:39004472
Major clinical research advances in gynecologic cancer in 2023: a tumultuous year for endometrial cancer., PMID:38330382
AZD1775 and anti-PD-1 antibody synergistically sensitize hepatoma to radiotherapy., PMID:38167245
Targeting DNA Damage and Repair Machinery via Delivering WEE1 Inhibitor and Platinum (IV) Prodrugs to Stimulate STING Pathway for Maximizing Chemo-Immunotherapy in Bladder Cancer., PMID:37849029
Empower the Potential of Trastuzumab Deruxtecan with Novel Combinations., PMID:37656059
Paediatric Strategy Forum for medicinal product development of DNA damage response pathway inhibitors in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration., PMID:37441939
Combined Wee1 and EGFR inhibition reveals synergistic antitumor effect in esophageal squamous cell carcinoma., PMID:37279554
Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers., PMID:37279095
Major clinical research advances in gynecologic cancer in 2022: highlight on late-line PARP inhibitor withdrawal in ovarian cancer, the impact of ARIEL-4, and SOLO-3., PMID:36890294
Targeted Therapies in the Treatment of Uterine Serous Carcinoma., PMID:36447064
CHK1 inhibition exacerbates replication stress induced by IGF blockade., PMID:34773074
WEE1 inhibition reverses trastuzumab resistance in HER2-positive cancers., PMID:33723720
Comparison of N- and C-terminally endogenously GFP-tagged WEE-1.3 strains in C. elegans., PMID:33474525
Predictive and Prognostic Value of DNA Damage Response Associated Kinases in Solid Tumors., PMID:33224881
Further Understanding of High-Grade Serous Ovarian Carcinogenesis: Potential Therapeutic Targets., PMID:33116896
A novel BCMA PBD-ADC with ATM/ATR/WEE1 inhibitors or bortezomib induce synergistic lethality in multiple myeloma., PMID:32060401
WEE1 inhibitor, AZD1775, overcomes trastuzumab resistance by targeting cancer stem-like properties in HER2-positive breast cancer., PMID:31866466
The therapeutic effectiveness of 177Lu-lilotomab in B-cell non-Hodgkin lymphoma involves modulation of G2/M cell cycle arrest., PMID:31836849
Combined Strategies with Poly (ADP-Ribose) Polymerase (PARP) Inhibitors for the Treatment of Ovarian Cancer: A Literature Review., PMID:31374917
Involvement of Myt1 kinase in the G2 phase of the first cell cycle in Xenopus laevis., PMID:31128913
MicroRNA-155 controls vincristine sensitivity and predicts superior clinical outcome in diffuse large B-cell lymphoma., PMID:30967394
Combined Aurora Kinase A (AURKA) and WEE1 Inhibition Demonstrates Synergistic Antitumor Effect in Squamous Cell Carcinoma of the Head and Neck., PMID:30755439
Inhibition of WEE1 kinase and cell cycle checkpoint activation sensitizes head and neck cancers to natural killer cell therapies., PMID:29925431
Expression, activation and clinical relevance of CHK1 and CHK2 in metastatic high-grade serous carcinoma., PMID:29804637
Identification of relevant drugable targets in diffuse large B-cell lymphoma using a genome-wide unbiased CD20 guilt-by association approach., PMID:29489886
Proteomics Profiling of CLL Versus Healthy B-cells Identifies Putative Therapeutic Targets and a Subtype-independent Signature of Spliceosome Dysregulation., PMID:29367434
WEE1 epigenetically modulates 5-hmC levels by pY37-H2B dependent regulation of IDH2 gene expression., PMID:29290954
UHRF1 is an Independent Prognostic Factor and a Potential Therapeutic Target of Esophageal Squamous Cell Carcinoma., PMID:29187878
Induction of G2M Arrest by Flavokawain A, a Kava Chalcone, Increases the Responsiveness of HER2-Overexpressing Breast Cancer Cells to Herceptin., PMID:28335434
Silencing Aurora-A with siRNA inhibits cell proliferation in human lung adenocarcinoma cells., PMID:27571708
Proteasome Inhibition Contributed to the Cytotoxicity of Arenobufagin after Its Binding with Na, K-ATPase in Human Cervical Carcinoma HeLa Cells., PMID:27428326
Wee1 Kinase Inhibitor AZD1775 Radiosensitizes Hepatocellular Carcinoma Regardless of TP53 Mutational Status Through Induction of Replication Stress., PMID:26975930
The Prozone Effect Accounts for the Paradoxical Function of the Cdk-Binding Protein Suc1/Cks., PMID:26854218
Sensitization of Pancreatic Cancers to Gemcitabine Chemoradiation by WEE1 Kinase Inhibition Depends on Homologous Recombination Repair., PMID:26585231
New perspectives in ovarian cancer treatment., PMID:24380827
Argonaute-1 functions as a mitotic regulator by controlling Cyclin B during Drosophila early embryogenesis., PMID:24165481
Cdk1 modulation ensures the coordination of cell-cycle events during the switch from meiotic prophase to mitosis., PMID:23871241
The circadian clock gene BMAL1 is a novel therapeutic target for malignant pleural mesothelioma., PMID:22510946
In vitro and in silico studies on substrate recognition and acceptance of human PKMYT1, a Cdk1 inhibitory kinase., PMID:22189141
Radiosensitization of human pancreatic cancer cells by MLN4924, an investigational NEDD8-activating enzyme inhibitor., PMID:22072567
Global profiling of signaling networks: study of breast cancer stem cells and potential regulation., PMID:21665913
Phenethyl isothiocyanate (PEITC) promotes G2/M phase arrest via p53 expression and induces apoptosis through caspase- and mitochondria-dependent signaling pathways in human prostate cancer DU 145 cells., PMID:21617228
The miR-290-295 cluster promotes pluripotency maintenance by regulating cell cycle phase distribution in mouse embryonic stem cells., PMID:20864249
cdc-25.2, a C. elegans ortholog of cdc25, is required to promote oocyte maturation., PMID:20200231
Switching in discoid domain receptor expressions in SLUG-induced epithelial-mesenchymal transition., PMID:18853422
MZ3 can induce G2/M-phase arrest and apoptosis in human leukemia cells., PMID:18491135
For research use only. Not for human or drug use.
